Skip to main content
Clinical Trials/ACTRN12624000554561
ACTRN12624000554561RecruitingUnknown

Prospective Study Evaluating The Treatment Outcomes For Localised Recurrent, Resectable Retroperitoneal Liposarcoma in adults.

Australia and New Zealand Sarcoma Association0 sites100 target enrollmentStarted: May 1, 2024Last updated:
Conditions

Trial Snapshot

Phase
Unknown
Status
Recruiting
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • 1. Aged 18 years or older presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)
  • 2. No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease
  • 3. Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only
  • 4. Sarcoma not originating from bone or abdominal or gynecological viscera
  • 5. Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)
  • 6. WHO performance status 0-2
  • 7. American Society of Anaesthesiologist (ASA) score 1-3
  • 8. No prior RT for the retroperitoneal liposarcoma
  • 9. Prior systemic therapy is allowed
  • 10. No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)
  • 11. Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment
  • 12. Patient deemed able to comply with study requirements according to investigator evaluation
  • 13. Signed ethics approved written informed consent

Exclusion Criteria

  • 1. Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team
  • 2. Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible
  • 3. Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease
  • 4. Myxoid liposarcoma histology
  • 5. Pregnancy

Investigators

Sponsor
Australia and New Zealand Sarcoma Association

Similar Trials